Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy prostate instrument

被引:544
作者
Esper, P
Mo, F
Chodak, G
Sinner, M
Cella, D
Pienta, KJ
机构
[1] Rush Med Coll, Chicago, IL 60612 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Chicago, Weiss Hosp, Chicago, IL 60637 USA
关键词
D O I
10.1016/S0090-4295(97)00459-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer. Methods, Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2(n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire, Results, Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change. Conclusions. Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer. (C) 1997, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:920 / 928
页数:9
相关论文
共 34 条
  • [1] BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V258, P2727
  • [2] Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946
  • [3] Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument
    Cella, DF
    McCain, NL
    Peterman, AH
    Mo, F
    Wolen, D
    [J]. QUALITY OF LIFE RESEARCH, 1996, 5 (04) : 450 - 463
  • [4] RELIABILITY AND VALIDITY OF THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY - LUNG (FACT-L) QUALITY-OF-LIFE INSTRUMENT
    CELLA, DF
    BONOMI, AE
    LLOYD, SR
    TULSKY, DS
    KAPLAN, E
    BONOMI, P
    [J]. LUNG CANCER, 1995, 12 (03) : 199 - 220
  • [5] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [6] CELLA DF, 1994, FACT MANUAL VERSION
  • [7] CELLA DF, 1990, P AN M AM SOC CLIN, V9, P307
  • [8] HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH ADVANCED PROSTATE-CANCER - A MULTINATIONAL PERSPECTIVE
    CLEARY, PD
    MORRISSEY, G
    OSTER, G
    [J]. QUALITY OF LIFE RESEARCH, 1995, 4 (03) : 207 - 220
  • [9] DAntonio LL, 1996, ARCH OTOLARYNGOL, V122, P482
  • [10] DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO